Scarica l'app Stockscreener
15.17
0.39%
-0.0523
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.22
Aprire:
$15.25
Volume 24 ore:
638.45K
Relative Volume:
0.55
Capitalizzazione di mercato:
$1.95B
Reddito:
$298.30M
Utile/perdita netta:
$298.21M
Rapporto P/E:
7.0101
EPS:
2.1637
Flusso di cassa netto:
$166.93M
1 W Prestazione:
-2.51%
1M Prestazione:
-5.13%
6M Prestazione:
-7.39%
1 anno Prestazione:
+87.62%
Intervallo 1D:
$15.07
$15.36
Intervallo di 1 settimana:
$15.06
$15.99
Portata 52W:
$7.285
$16.88
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Nome
Aurinia Pharmaceuticals Inc
Settore
Industria
Telefono
250-744-2487
Indirizzo
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
15.16 | 1.96B | 298.30M | 298.21M | 166.93M | 2.1637 |
VRTX
Vertex Pharmaceuticals Inc
|
437.30 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.04 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.30 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.32 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.14 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2025-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-30 | Ripresa | H.C. Wainwright | Buy |
| 2022-11-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-05-05 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-28 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-05-05 | Iniziato | Cowen | Outperform |
| 2020-01-10 | Iniziato | Jefferies | Buy |
| 2019-12-16 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-16 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-10-30 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-03-22 | Reiterato | FBR & Co. | Outperform |
| 2016-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-17 | Reiterato | H.C. Wainwright | Buy |
| 2016-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-08 | Iniziato | MLV & Co | Buy |
Mostra tutto
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Aurinia (AUPH) Chief Legal Officer granted 115,541 performance stock units - Stock Titan
Aurinia Pharmaceuticals (AUPH) grants PSUs and stock options to CFO - Stock Titan
Aurinia (AUPH) COO receives 116,144 PSUs and 70,230 stock options - Stock Titan
Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences - citybiz
Tranche Update on Aurinia Pharmaceuticals Inc.'s Equity Buyback Plan announced on February 15, 2024. - marketscreener.com
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Tangible book value per share of Aurinia Pharmaceuticals Inc. – FWB:IKAP - TradingView
Aurinia Pharmaceuticals stock (CA05156H1070): Q1 revenue beat and July earnings date in focus - AD HOC NEWS
Jefferies Upgrades Aurinia Pharmaceuticals (AUPH) - MSN
Behavioral Patterns of AUPH and Institutional Flows - Stock Traders Daily
Aurinia Pharmaceuticals (AUPH) Price Target Increased by 34.15% to 16.03 - MSN
Aurinia Pharmaceuticals' (NASDAQ:AUPH) Performance Raises Some Questions - simplywall.st
We Believe Aurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings Are A Poor Guide For Its Profitability - Yahoo Finance
Kezar Life Sciences stock (US49374L1008): Merger with Aurinia completes, shares cancelled - AD HOC NEWS
Aurinia Pharmaceuticals IncCommon Shares (NQ: AUPH - FinancialContent
Aurinia deal leaves Kezar (KZR) wholly owned as Tang Capital exits - Stock Titan
Aurinia Pharmaceuticals stock (CA05156H1070): Announces $6.955 Cash Acquisition of Kezar Life Scienc - AD HOC NEWS
AUPH stock sees biggest single-day drop in more than 9 months despite Q1 earnings beat – here’s what’s spooking investors - MSN
TradingKey - TradingKey
Kezar Life Sciences stock (US49374L1008): Aurinia completes $51.4M acquisition - AD HOC NEWS
Kezar Life Sciences (NASDAQ: KZR) COO disposes shares, options in Aurinia merger - Stock Titan
Aurinia deal cashes out Kezar (NASDAQ: KZR) CEO shares and options - Stock Titan
Kezar (KZR) director exits stake as Aurinia deal pays $6.955 plus CVRs - Stock Titan
Kezar (KZR) SVP tenders shares as Aurinia merger cancels stock options - Stock Titan
Morgan Stanley Smith Barney to sell 3.14M AUPH shares (AUPH) on 05/11/2026 - Stock Titan
AUPH (NASDAQ: AUPH) Proposed sale of 717,688 common shares - Stock Titan
500,503 AUPH shares listed for resale by Morgan Stanley (NASDAQ: AUPH) - Stock Titan
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences By Investing.com - Investing.com Nigeria
Aurinia Pharmaceuticals completes acquisition of Kezar Life Sciences - Investing.com UK
Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences - TipRanks
Kezar Life Sciences Acquired by Aurinia, Delisted From Nasdaq - TipRanks
Kezar Life Sciences acquired by Aurinia Pharma U.S.; Nasdaq delisting follows - Investing.com Nigeria
Aurinia acquires Kezar Life Sciences (NASDAQ: KZR) in cash-and-CVR deal - Stock Titan
Aurinia Pharmaceuticals (NASDAQ: AUPH) closes Kezar Life Sciences cash-and-CVR deal - Stock Titan
Aurinia (KZR) completes merger with Kezar — $6.955 per share plus CVR - Stock Titan
Aurinia to acquire Kezar Life Sciences (NASDAQ: KZR) in cash and CVR deal - Stock Titan
Aurinia Pharmaceuticals stock (CA05156H1070): Lupus drug developer eyes broader kidney disease marke - AD HOC NEWS
Aurinia Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - Moomoo
Aurinia Pharmaceuticals Inc. Just Beat EPS By 28%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) Is Up 6.3% After Stronger Q1 LUPKYNIS-Driven Profitability Has The Bull Case Changed? - Sahm
Aurinia Pharmaceuticals (AUPH) Q1 EPS Of US$0.26 Tests Bullish Margin Narratives - Sahm
Aurinia Pharmaceuticals Sees 2026 Rev $315M-$325M >AUPH - Moomoo
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress - BioSpace
AUPH: Aurinia Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
AUPH Stock Sees Biggest Single-Day Drop In More Than 9 Months Despite Q1 Earnings Beat – Here’s What’s Spooking Investors - Stocktwits
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates - Yahoo Finance
Aurinia (NASDAQ: AUPH) boosts Q1 profit, buys back stock and moves to acquire Kezar - Stock Titan
Aurinia (NASDAQ: AUPH) boosts Q1 profit, cash flow and reaffirms 2026 outlook - Stock Titan
Earnings Flash (AUPH) Aurinia Pharmaceuticals Posts Q1 EPS $0.25, Vs. FactSet Est of $0.20 - Moomoo
Aurinia Pharmaceuticals Inc Azioni (AUPH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):